Request Sample
for OFFICE

 

Request Sample
for PATIENT

 

Request for
MEDICAL INFORMATION

Slynd® is safe and effective

Slynd® has an efficacy profile that is comparable to other oral contraceptive options9

Chart detail more an less effective forms of birth control

17 (1.8%) pregnancies
out of 953 females
evaluated2,3

 

4.0 Pearl Index
(2.3, 6.4; 95% CI)
out of 5547
evaluable cycles

Efficacy and safety were assessed in an open-label, prospective, multi-center, non-controlled trial of 1552 enrolled female subjects, aged 15 and above.

 

Subjects received a 24-day regimen of drospirenone tablets, 4 mg swallowed for up to 13 28-day cycles, providing a total of 5,547 evaluable cycles.

 

A total of 352 women completed 13 cycles of treatment.

Slynd® is safe…

 

Evaluated in over 20,000 cycles3

Slynd is not contraindicated in patients with cardiovascular disease2

– Studies have not indicated an association between progestin-only preparations and an increased risk of myocardial infarction, cerebral thromboembolism, or venous thromboembolism10

Highlights on Drospirenone

Drospirenone has similar biochemical and pharmacological profile to bioidentical progesterone4

Progestin Comparison5

*Table includes comparison of most commonly found progesterones in the US oral contraceptive market.

Anti-Mineralocorticoid Activity

 

Drospirenone counteracts estrogen-induced stimulation of the renin-angiotensin aldosterone system which can result in reduced fluid retention6

 

Anti-Androgenic Activity

 

Drospirenone has no androgenic activity, and is reported to improve androgenic-related skin disorders7,8

*Table includes comparison of most commonly found progesterones in the US 
oral contraceptive market. Progestational and androgenic activity are relative to 1 mg dose of norethindrone.8

Tolerable bleeding profile…3

Slynd® results show a tolerable bleeding profile

 Discontinuation rate is less than 1%*

– 91 subjects (0.4% of exposure cycles*) discontinued Slynd™ due to bleeding irregularities

 

 Results showed a decrease over time in
 unscheduled bleeding from 64.4% in cycle 1 
to 40.3% in cycle 13

 

  Scheduled bleeding decreased from 81.2% in cycle 1 to 26.4% in cycle 13

…and 24-hour missed pill intake window11

Slynd® is the first and only POP with a 24-hour intake window similar to COCs3,11

Slynd® is the only POP with a 24+4 dosing regimen

24 white (active) pills 

each containing 4 mg of drospirenone for Weeks 1 through 3 and the first 3 days of Week 4 (Days 1-24)

4 green (placebo) pills

for the last 4 days of Week 4 (Days 25-28)

24 white (active) pills 

each containing 4 mg of drospirenone for Week 1 through Week 3 and the first 3 days of Week 4 (Days 1-24)

4 green (placebo) pills

for the last 4 days of Week 4 (Days 25-28)

References (click to expand)

1. Villavicencio J, Allen RH. Unscheduled bleeding and contraceptive choice: increasing satisfaction and continuation rates. Open Acc J Contracept. 2016;7:43-52. doi: 10.2147/OAJC.S85565
2. Slynd [package insert]. Exeltis USA, Inc.; Florham Park, NJ; 2019.
3. Data on file. Exeltis USA, Inc.; Florham Park, NJ; 2019.
4. Fuhrmann U, Krattenmacher R, Slater ED, et al. The novel progestin drospirenone and its natural counterpart progesterone: biochemical profile and antiandrogenic potential. Contraception. 1996;54(4):243-251
5. Regidor PA, Schindler AE. Antiandrogenic and antimineralocorticoid health benefits of COC containing newer progestins: dienogest and drospirenone. Oncotarget. 2017:8 (47): 83334-83342.
6. Vroonen L, Cavalier E, Vranken L, et al. Influence of drospirenone on renin-angiotensin-aldosterone system evaluation. Endocrine Abstracts. 2011;26:12.
7. Slopien R, Milewska E, Rynio P, et al. Use of oral contraceptives for management of acne vulgaris and hirsutism in women of reproductive and late reproductive age. Menopause Review. 2018;17(1):1-4. doi: 10.5114/pm.2018.74895
8. Greer JB, Modugno F, Allen G, et al. Androgenic progestins in oral contraceptives and the risk of epithelial ovarian cancer. Obstet Gynecol. 2005;105:731-740.
9. Batur P. Female contraception. Cleveland Clinic Center for Continuing Education. Published December 2016.
10. Glisic M, Shahzad S, Tsoli S, et al. Association between progestin-only contraceptive use and cardiometabolic outcomes: a systematic review and meta-analysis Eur J Prev Cardiol. 2018;25(10):1042-1052. doi: 10.1177/2047487318774847.
11. Duijkers IJM, Heger-Mahn D, Drouin D, et al. Maintenance of ovulation inhibition with a new progestogen-only pill containing drospirenone after scheduled 24-h delays in pill intake. Contraception. 2016:93(4): 303-309.

X

Please confirm the following information:

Your Name*

Practice Location*

Your NPN*

Bitnami